SEARCH

SEARCH BY CITATION

References

  • 1
    Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001; 7(Suppl. 2): 2531.
  • 2
    Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37(Suppl. 3): S26580.
  • 3
    Brik A, Salem AM, Kamal AR et al. Surgical outcome of pulmonary aspergilloma. Eur J Cardiothorac Surg 2008; 34: 8825.
  • 4
    Riscili BP, Wood KL. Noninvasive pulmonary Aspergillus infections. Clin Chest Med 2009; 30: 31535. vii.
  • 5
    Lee JG, Lee CY, Park IK et al. Pulmonary aspergilloma: analysis of prognosis in relation to symptoms and treatment. J Thorac Cardiovasc Surg 2009; 138: 8205.
  • 6
    Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 2011; 89: 86472.
  • 7
    Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 1997; 112: 5418.
  • 8
    British Thoracic and Tuberculosis Association. Aspergilloma and residual tuberculous cavities–the results of a resurvey. Tubercle 1970; 51: 22745.
  • 9
    Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 32760.
  • 10
    Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 2006; 52: e1337.
  • 11
    Camuset J, Nunes H, Dombret MC et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 2007; 131: 143541.
  • 12
    Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990; 23: 60714.
  • 13
    De Beule K, De Doncker P, Cauwenbergh G et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses 1988; 31: 47685.
  • 14
    Campbell JH, Winter JH, Richardson MD, Shankland GS, Banham SW. Treatment of pulmonary aspergilloma with itraconazole. Thorax 1991; 46: 83941.
  • 15
    Lebeau B, Pelloux H, Pinel C et al. Itraconazole in the treatment of aspergillosis: a study of 16 cases. Mycoses 1994; 37: 1719.
  • 16
    Guazzelli LS, Xavier MO, Oliveira FdM, Severo LC. Chronic cavitary pulmonary aspergillosis and fungal balls. In: Pasqualotto AC (ed.), Aspergillosis: From Diagnosis to Prevention. New York: Springer, 2009: 585620.
  • 17
    Tsubura E. Multicenter clinical trial of itraconazole in the treatment of pulmonary aspergilloma. Pulmonary Aspergilloma Study Group. Kekkaku 1997; 72: 55764.
  • 18
    Kohno S, Masaoka T, Yamaguchi H et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36: 3729.
  • 19
    Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 2006; 119: 527. e17–24.
  • 20
    Hagiwara E, Sekine A, Sato T et al. Clinical features of chronic necrotizing pulmonary aspergillosis treated with voriconazole in patients with chronic respiratory disease. Nihon Kokyuki Gakkai Zasshi 2008; 46: 8649.
  • 21
    Yasuda S, Ohnishi R, Suzuki T, Sano K, Kato T. Short-term efficacy evaluation of chronic pulmonary aspergillosis treated with micafangin and maintenance therapy of itraconazole. Nihon Kokyuki Gakkai Zasshi 2009; 47: 98590.
  • 22
    Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning DW. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 2010; 51: 138391.
  • 23
    Kohno S, Izumikawa K, Ogawa K et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 2010; 61: 4108.
  • 24
    Nam HS, Jeon K, Um SW et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis 2010; 14: e47982.
  • 25
    Kohno S, Izumikawa K, Kakeya H et al. Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study. Med Mycol 2011; 49: 68893.
  • 26
    Tomioka H, Kaneda T, Kida Y et al. An open, noncomparative multicenter study of the efficacy and safety of itraconazole injections and high dose capsules in chronic pulmonary aspergillosis. Kansenshogaku Zasshi 2011; 85: 64451.
  • 27
    Cadranel J, Philippe B, Hennequin C et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis 2012; 31: 32319.
  • 28
    Fujita M, Tao Y, Kajiki A et al. The clinical efficacy and safety of micafungin-itraconazole combination therapy in patients with pulmonary aspergilloma. J Infect Chemother 2012; 18: 66874.
  • 29
    Saito T, Fujiuchi S, Tao Y et al. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan. Infection 2012; 40: 6617.
  • 30
    Yoshida K, Kurashima A, Kamei K et al. Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in multicenter study. J Infect Chemother 2012; 18: 37885.
  • 31
    Pratap H, Dewan RK, Singh L, Gill S, Vaddadi S. Surgical treatment of pulmonary aspergilloma: a series of 72 cases. Indian J Chest Dis Allied Sci 2007; 49: 2327.
  • 32
    Akbari JG, Varma PK, Neema PK, Menon MU, Neelakandhan KS. Clinical profile and surgical outcome for pulmonary aspergilloma: a single center experience. Ann Thorac Surg 2005; 80: 106772.